NAAG Urges TikTok and Snapchat to Give Parents More Control

March 29, 2022

The National Association of Attorneys General (NAAG) sent a letter, signed by 44 attorneys general, to TikTok and Snapchat urging them to give parents the ability to monitor their children’s social media usage and protect their children from online threats using parental control apps. In their letter, the attorneys general express various concerns over the…

Read More →

NAAG Urges FTC to Create Robust Rule Outlawing Impersonation Scams

February 23, 2022

The National Association of Attorneys General (NAAG) sent a letter signed by 49 attorneys general in response to a request for comments by the Federal Trade Commission (FTC) on a federal rule to combat impersonation scams. The letter raises concerns about the plethora of impersonation scams targeting consumers and the current lack of a national rule…

Read More →

NAAG Responds to FDA’s Comment Request on New Over-The-Counter Hearing Aid Rules

January 18, 2022

In response to a request for comments from the Food and Drug Administration (FDA) regarding new rules regulating over-the-counter hearing aids, NAAG submitted comments encouraging the FDA to take the below steps to ensure that states maintain a role as regulators in this emerging market: The FDA should define preemption terms in a way that…

Read More →

NAAG Challenges Efforts to Weaken Laws Against Human Trafficking & Sexual Abuse

December 9, 2021

The National Association of Attorneys General (NAAG) wrote a letter to the American Law Institute (ALI) urging them to reject proposed changes to Section 213 of the Model Penal Code (MPC) that would weaken the ability of states to prosecute sexual assault, abuse, exploitation, and trafficking crimes; jeopardize the safety of victims of these crimes;…

Read More →

NAAG Endorses Bankruptcy Venue Reform Act of 2021

November 9, 2021

We support H.R. 4193, and S. 2827, the Bankruptcy Venue Reform Act of 2021.

Read More →

NAAG Supports Senate Hearings on Social Media and Mental Health

October 5, 2021

As enforcers of our jurisdictions’ consumer protection laws, we find it deeply troubling that Facebook and other social media platforms seek to increase user engagement by conscripting our nation’s youth despite known harms to children and adolescents.

Read More →

Colorado et al. v. Google, No. 1:30-cv-03715 (D.D.C. Dec. 17, 2020)

July 12, 2021

Thirty-eight states sued Google, alleging that Google illegally maintains its monopoly power over general search engines and related general search advertising markets through a series of anticompetitive contracts and conduct, hurting both consumers and advertisers. Consumers are denied the benefits of competition, including the possibility of higher quality services and better privacy protections. Advertisers are…

Read More →

NAAG Submits Comment Letter on Beneficial Ownership Regulations

May 6, 2021

Our comments are consistent with the sense of Congress, which requires that regulations “to the greatest extent practicable… collect information in a form and manner that is reasonably designed to generate a database that is highly useful to… law enforcement agencies…” NDAA § 6402(8)(C).

Read More →

State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)

October 9, 2020

Plaintiff states alleged that the makers of Suboxone, a drug used to treat opioid addiction, engaged in a scheme to block generic competitors and raise prices. Specifically, they are conspiring to wtich Suboxone from a tablet version to a flim in order to prevent or delay generic entry. The states allege that the manufacturers engaged in “product hopping” in which a company makes slight changes to its product to extend patent protections and prvent generic alternatives. The complaint was filed under seal.

Read More →

Texas et al. v. Organon (Remeron), No. 04-5126 (D.N.J. 2004)

October 9, 2020

Plaintiff states settled with drug maker Organon USA, Inc. and its parent company, Akzo Nobel N.V., resolving antitrust claims involving the antidepressant drug Remeron between June 2001 and October 2004. The states’ complaint alleged that Organon unlawfully extended its monopoly by improperly listing a new “combination therapy” patent with the U.S. Federal Drug Administration. In addition, the complaint alleged that Organon delayed listing the patent with the FDA in another effort to delay the availability of lower-cost generic substitutes. The $26 million settlement resolved claims brought by state attorneys general, as well as a private class action brought on behalf of a class of end payors. Organon also agreed to make timely listings of patents and to submit accurate and truthful information to the FDA.

Read More →